According to SCYNEXIS's latest financial reports the company's current earnings (TTM) are $76.63 M. In 2022 the company made an earning of -$62.32 M a decrease over its 2021 earnings that were of -$33.3 M.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | $76.63 M | -222.99% |
2022 | -$62.32 M | 87.15% |
2021 | -$33.3 M | -41.74% |
2020 | -$57.16 M | 8.41% |
2019 | -$52.72 M | 205.58% |
2018 | -$17.26 M | -25.66% |
2017 | -$23.21 M | -31.73% |
2016 | -$34 M | 19.9% |
2015 | -$28.36 M | 111.45% |
2014 | -$13.41 M | -27.82% |
2013 | -$18.58 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Galmed Pharmaceuticals
GLMD | -$7.54 M | -109.83% | ๐ฎ๐ฑ Israel |
Catalyst Pharmaceuticals CPRX | $94.51 M | 23.33% | ๐บ๐ธ USA |
Catalent CTLT | -$1.21 B | -1,675.00% | ๐บ๐ธ USA |
KemPharm KMPH | -$41.91 M | -154.68% | ๐บ๐ธ USA |